biontech - Search News

Order byBest matchMost fresh

News

BioNTech to buy German rival CureVac for $1.25B

· 1d · on MSN

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

Continue reading

BioNTech to Buy CureVac for $1.25 Billion for Cancer Boost

MedCity News · 1d

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

2don MSN

BioNTech kauft CureVac für $1,25 Mrd., stärkt Onkologiegeschäft

BioNTech hat vereinbart, den ehemaligen Corona-Impfstoffkonkurrenten CureVac für rund 1,25 Milliarden Dollar (1,08 Milliarden ...

1d

BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

Pharmalittle: We’re reading about Trump and drug prices, BioNTech buying Curevac, and more

The Trump administration had said it would disclose by Wednesday the target prices for drugs, but pharma companies are still ...

1d

Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz

The major averages were mixed near noon with the Dow the laggard as a pullback in Boeing weighs on the Industrials index. U.S ...

1d

Stock Movers: GameStop, BioNTech, Oracle

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results